Portfolio expansion achieved with acquisition of Galidesivir
Filed with ASX · · 6 pages · English
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- Successful Phase 2 clinical trial of ISLA-101
- Island completes $3.6 million placement
- Quarterly Activities & Cashflow Report
- Phase 2a/b clinical trial update
- Completion of patient dosing in Phase 2b clinical trial
Later from Island Pharmaceuticals
- Completion of Galidesivir transaction
- Options exercise from existing substantial shareholder
- Preliminary Final Report
- FDA meeting request lodged for Galidesivir
- FDA Meeting request granted
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals